Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder

Journal of Clinical Psychiatry

Volumn 78, Issue 1, 2017, Pages 115-121

  McIntyre, Roger S ^a   Florea, Ioana ^b   Tonnoir, Brigitte ^c   Loft, Henrik ^b   Lam, Raymond W ^d   Christensen, Michael Cronquist ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b H LUNDBECK A S   (Denmark)

^c Lundbeck   (France)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antidepressants; Depression

Indexed keywords

PLACEBO; VORTIOXETINE; PIPERAZINE DERIVATIVE; SULFIDE;

ADULT; AGED; ARTICLE; CLINICAL OUTCOME; COGNITION; DIGIT SYMBOL SUBSTITUTION TEST; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY (TOPIC); PERCEIVED DEFICITS QUESTIONNAIRE; POST HOC ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; STROOP TEST; TRAIL MAKING TEST; WORK; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PRODUCTIVITY; PSYCHOLOGY; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; COGNITIVE DYSFUNCTION; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EFFICIENCY; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; PSYCHOMETRICS; SULFIDES; TREATMENT OUTCOME;

EID: 85012939635     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.16m10744     Document Type: Article

References (34)

1. Lam RW, Parikh SV, Michalak EE, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry. 2015;27(2):142-149.
2. Adler DA, McLaughlin TJ, Rogers WH, et al. Job performance deficits due to depression. Am J Psychiatry. 2006;163(9):1569-1576.
3. Olesen J, Gustavsson A, Svensson M, et al; CDBE2010 study group; European Brain Council. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155-162.
4. Woo JM, Kim W, Hwang TY, et al. Impact of depression on work productivity and its improvement after outpatient treatment with antidepressants. Value Health. 2011;14(4):475-482.
5. Harvey SB, Glozier N, Henderson M, et al. Depression and work performance: an ecological study using web-based screening. Occup Med (Lond). 2011;61(3):209-211.
6. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011;41(6):1165-1174.
7. McIntyre RS, Soczynska JZ, Woldeyohannes HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015;56:279-282.
8. Buist-Bouwman MA, Ormel J, de Graaf R, et al; ESEMeD/MHEDEA 2000 investigators. Mediators of the association between depression and role functioning. Acta Psychiatr Scand. 2008;118(6):451-458.
9. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebocontrolled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557-1567.
10. Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebocontrolled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025-2037.
11. H. Lundbeck A/S. European Medicines Agency Summary of Product Characteristics. Brintellix. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002717/WC500159449.pdf. Accessed June 11, 2015.
12. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebocontrolled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-223.
13. Ferrari AJ, Charlson FJ, Norman RE, et al. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One. 2013;8(7):e69637.
14. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65(8):870-880.
15. Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31(5):569-576.
16. Drago A, Serretti A. Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR∗D study and an independent trial. J Clin Psychopharmacol. 2011;31(3):345-348.
17. Baune BT, Miller R, McAfoose J, et al. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176(2-3):183-189.
18. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482-491.
19. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953-959.
20. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebocontrolled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138-149.
21. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26(11):1408-1416.
22. Wade AG, Fernandez JL, Francois C, et al. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmacoeconomics. 2008;26(11):969-981.
23. Rund BR, Sundet K, Asbjornsen A, et al. Neuropsychological test profiles in schizophrenia and non-psychotic depression. Acta Psychiatr Scand. 2006;113(4):350-359.
24. Lee RS, Hermens DF, Porter MA, et al. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012;140(2):113-124.
25. Rock PL, Roiser JP, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029-2040.
26. Spates R, Pagoto S, Kalata A. A qualitative and quantitative review of behavioral activation treatment of major depressive disorder. Behav Anal Today. 2006;7(4):508-521.
27. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr. 2013;18(3):139-149.
28. Agrigoroaei S, Lachman ME. Cognitive functioning in midlife and old age: combined effects of psychosocial and behavioral factors. J Gerontol B Psychol Sci Soc Sci. 2011;66(suppl 1):i130-i140.
29. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43-57.
30. Insel N, Frankland PW. Mechanism, function, and computation in neural systems. Behav Processes. 2015;117:4-11.
31. Galinowski A, Miranda R, Lemaitre H, et al; IMAGEN Consortium. Resilience and corpus callosum microstructure in adolescence. Psychol Med. 2015;45(11):2285-2294.
32. Smith MM, Saklofske DH, Keefer KV, et al. Coping strategies and psychological outcomes: the moderating effects of personal resiliency. J Psychol. 2016;150(3):318-332.
33. European Depression Association (EDA). IDEA: Impact of Depression at Work in Europe Audit-Final Report. October 2012. http://eddas.eu/wp-content/uploads/2016/04/IDEA-Survey-depression-in-the-workplace-results.pdf. Accessed July 28, 2015.
34. Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12(5):224-231.